G28 Stock Overview
Operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tevogen Bio Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.32 |
| 52 Week High | US$8.65 |
| 52 Week Low | US$0.24 |
| Beta | -1.03 |
| 11 Month Change | -50.00% |
| 3 Month Change | 166.13% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| G28 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.1% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how G28 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how G28 performed against the German Market.
Price Volatility
| G28 volatility | |
|---|---|
| G28 Average Weekly Movement | 67.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G28's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G28's weekly volatility has increased from 41% to 67% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 19 | Ryan Saadi | tevogen.com |
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer.
Tevogen Bio Holdings Inc. Fundamentals Summary
| G28 fundamental statistics | |
|---|---|
| Market cap | €237.26m |
| Earnings (TTM) | -€4.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-52.2x
P/E RatioIs G28 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G28 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.50m |
| Earnings | -US$4.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -43.0% |
How did G28 perform over the long term?
See historical performance and comparison